Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors [PDF]
Microorganisms, 2021 Despite the emerging threat of the Mayaro virus (MAYV) in Central and South-America, there are no licensed antivirals or vaccines available for this neglected mosquito-borne virus.
Lana Langendries +2 more
exaly +9 more sources
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo [PDF]
Viruses, 2022 Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children.
Wu Zhong, Ruiyuan Cao, Yunzheng Yan
exaly +6 more sources
EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir [PDF]
ACS OmegaEIDD-1931 is the active form of molnupiravir, an orally effective drug approved by the United States Food and Drug Administration (USFDA) against COVID-19. Pharmacokinetic alteration can cause untoward drug interaction (drug-drug/disease-drug), but hardly any information is known about this recently approved drug.
Debaraj Mukherjee, , Utpal Nandi
exaly +5 more sources
Nucleoside analogue EIDD-1931 in the treatment of naturally occurring feline infectious peritonitis [PDF]
Journal of Feline Medicine and SurgeryObjectives Current antiviral therapy for feline infectious peritonitis (FIP) has limited availability and can be cost-prohibitive. The nucleoside analogue EIDD-1931 is an effective inhibitor against FIP virus serotype I and II in vitro. Our objective was
Alexandra Kennedy, Joanna White
doaj +4 more sources
9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2 [PDF]
Scientific ReportsThe 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), and RNA-dependent RNA polymerase (RdRp) are key enzymes in SARS-CoV-2 replication and serve as critical targets for an antiviral drug.
Kabita Pandey +10 more
doaj +4 more sources
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression [PDF]
Viruses, 2023 The host targeting antiviral, UV-4B, and the RNA polymerase inhibitor, molnupiravir, are two orally available, broad-spectrum antivirals that have demonstrated potent activity against SARS-CoV-2 as monotherapy.
Evelyn J. Franco +4 more
doaj +2 more sources
Clinical and Translational Science, 2022 The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the ...
Raymond K. Hau +2 more
doaj +2 more sources
Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines [PDF]
VirusesFeline infectious peritonitis (FIP) is a disease arising as a result of feline coronavirus infection. It used to be regarded a fatal disease, with euthanasia commonly recommended following diagnosis due to its very poor prognosis.
Séverine Tasker +15 more
doaj +2 more sources
Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI [PDF]
Frontiers in Digital HealthIntroductionSince the outbreak of the COVID-19 pandemic, extensive efforts including vaccine and drug development have been accentuated to address the emergence of SARS-CoV-2 variants.
Peter Wang +39 more
doaj +2 more sources
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens [PDF]
npj Digital Medicine, 2022 IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 ...
Agata Blasiak +20 more
doaj +2 more sources